The report notes an EBITDA beat and raised growth/margin guidance from the company, maintaining ADD with a revised target price.
Read this note →Metropolis Healthcare Limited
NSE METROPOLIS BSE 542650 INE112L01020
0 filings · 0 analysed
582.35
+10.98%
over 5 years
-
HSIE Results Daily 05 Nov 26 HSIE
The report notes an EBITDA beat and raised growth/margin guidance from the company, maintaining ADD with a revised target price.
-
Pharma and Healthcare Q2FY27 Preview HSIE
The report expects 15% YoY revenue growth led by patient and test volumes with EBITDA margin improvement, naming it a strong performer.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 05 Nov 2026, 06:50 | long | 581.25 | 660.00 | 568.75 | -16% | open by 2027-11-05 |
| HDFC Securities | 07 Oct 2026, 15:25 | long | 541.45 | 650.00 | 568.75 | 25% | open by 2027-10-07 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report expects 15% YoY revenue growth led by patient and test volumes with EBITDA margin improvement, naming it a strong performer.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief